NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,184+0.52%BTC$86,009−0.55%VIX16.17+5.62%live tape · as of 13:03 UTC
The Screen · Technology · Semiconductors
ST Microelectronics
STM · the NYSE · USD · Market cap $47.7B · 48,000 employees
STMicroelectronics N.V., together with its subsidiaries, designs, develops, manufactures, and sells semiconductor products in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price53.50 USD
Fair value47.49
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation53.50+0.0% to today ✓
2026-08-24Read Distribution53.28+0.4% to today
2026-07-16Read Markup77.30-30.8% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ST Microelectronics holds its Accumulation at $53.50. The statistical read favours the sellers, held for 2 days.
As held on the ledger · 2026-10-01
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 2 days
Price at the screen
$53.50
Valuation
N/A trailing · 21.05 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.51
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.49%
Below 33%
Interest-bearing debt is just 9.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.77%
Below 33%
Cash held in interest-bearing accounts and securities is 0.8% of assets, under the one-third limit.
Pass
Receivables
18.48%
Below 49%
Money owed to the company is 18.5% of assets, under the 49% limit.
Pass
Revenue purity
1.89%
Below 5%
Only 1.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
ST Microelectronics clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. The price runs 11.2% above the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +37% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chip cycles swing from feast to famine
Picture a factory that races to meet demand only to watch orders vanish when phones and cars slow. That pattern defines much of the semiconductor trade, and ST Microelectronics sits right in its path. Revenue is rising 23 percent, yet profit margins sit at just 1 percent and return on equity is equally thin, leaving little cushion when the cycle turns.
We pass on the shares. The price of 62 dollars sits well above our fair value of 45 dollars, a negative margin of safety that already prices in optimistic growth. A forward multiple of 24.9 times adds to the stretch, and the narrow moat offers scant protection against bigger rivals in a capital-heavy industry.
The real danger is the classic cyclical trap. Low returns today can look like a bargain until peak earnings fade and multiples compress further. Analyst targets may sit higher, yet those forecasts often assume the upswing lasts. Ethical screening clears, but valuation and cycle risk do not. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
STM trades on the NYSE (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64.
2026-07-23Markup$62.06+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Markup$62.06+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Markup$62.06+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$62.06+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markup$62.06-19.7%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 19.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$77.30+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Markup$77.30+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Markup$77.30+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 130% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 136%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (13 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.